Trending...
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
- Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
- Retired Hobbyist Launches Bold Weekly Album Project Using AI Songwriting Tools
Expansion accommodates significant growth in demand for its new rapid point-of-care HIV tests intended to break the chain of new HIV infections worldwide
BEAVERTON, Ore. - AussieJournal -- Sedia Biosciences Corporation, formerly of Portland Oregon, today announced the relocation to and opening of their new assay development and manufacturing facility in Beaverton, Oregon. The 27,000 square foot facility provides for both current growth as well as additional near-term expansion and enables immediate scale-up of manufacturing capacity as well as research capabilities. Equipped with multiple state of the art, environmentally controlled production, quality and research laboratories, high throughput production equipment, and expanded warehouse capacity, the facility is also designed to accommodate the "new normal" of business in a pandemic challenged environment. The new facility will have a much needed immediate impact on production capacity of Sedia's products, now being used in partnership with the U.S. Centers for Disease Control and Prevention (CDC, www.cdc.gov), PEPFAR (President's Emergency Plan for AIDS Relief, www.pepfar.gov), and other NGOs and stakeholders working with Sedia.
More on Aussie Journal
Dr. Ronald Mink, Chief Science Officer and President, who co-founded Sedia with Roger Gale, Sedia's CEO and Chairman, stated that "Sedia has been focused on fulfilling the growing demand from CDC, PEPFAR and others for our AsantéTM HIV Rapid Recency® Assay. This test is the first rapid point-of-care assay with the capability to both quickly verify HIV status of a patient, and determine if they are a recent, or 'new' infection. Public Health agencies worldwide use this valuable information to identify where new outbreaks of HIV are occurring. Tracking these early cases is important as they have the highest likelihood of transmitting HIV and may be doing so unknowingly. Such individuals can be the source of new and sudden outbreaks of the disease. Our products are intended to break this cycle. COVID has shown that what the world needs is simple, fast and accurate diagnostic tests in large numbers. This is what we do. Sedia is dynamic, growing rapidly and is very relevant to the current global health crisis."
According to Nancy Lime, Vice President Operations, "Globally, an estimated 19% of persons living with HIV are unaware of their status. Individuals with recent HIV infections can be responsible for up to 40% of new infections in their community. Since HIV can remain asymptomatic and undetected for months, recently infected individuals can continue to pass the virus to others. New approaches and tools are needed to fight HIV and other global pandemics and this technology can potentially be applied to other diseases, including the SARS-CoV-2 'COVID-19' virus and sexually transmitted diseases."
More on Aussie Journal
About Sedia Biosciences Corporation
Sedia Biosciences is a privately held medical device and diagnostics company founded in 2009 and is based in Beaverton, Oregon, USA. Our commitment is to become a leader in three areas intended to advance global access to care: (1) state-of-the-art rapid point-of-care diagnostic assays, (2) novel epidemiological disease surveillance assays and other Public Health tools and (3) innovative clinical specimen collection devices to improve and facilitate remote collection of specimens for follow-up testing. Sedia brings together a dedicated team of scientists and business people that share a common mission: to improve access to medical care around the world by providing innovative diagnostic, epidemiological and clinical products.
Follow us on Facebook, LinkedIn, Twitter or at our website: www.sediabio.com
More on Aussie Journal
- BIYA Forecasts 2025 Surge with ¥300M ($41.8 M USD) in Revenue and ¥25M Profit from Cloud Based HR Solutions: Baiya Intl. Group (N A S D A Q: BIYA)
- Paul E. Saperstein Co. Announces Geographic Expansion of Auction Services
- Florida Broker Bent Danholm Featured in the Daily Mail's U.S. Real Estate Coverage
- Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams
- Melissa B. Releases Digitally Independent: Empowering Music Artists with AI and Brand Strategy
Dr. Ronald Mink, Chief Science Officer and President, who co-founded Sedia with Roger Gale, Sedia's CEO and Chairman, stated that "Sedia has been focused on fulfilling the growing demand from CDC, PEPFAR and others for our AsantéTM HIV Rapid Recency® Assay. This test is the first rapid point-of-care assay with the capability to both quickly verify HIV status of a patient, and determine if they are a recent, or 'new' infection. Public Health agencies worldwide use this valuable information to identify where new outbreaks of HIV are occurring. Tracking these early cases is important as they have the highest likelihood of transmitting HIV and may be doing so unknowingly. Such individuals can be the source of new and sudden outbreaks of the disease. Our products are intended to break this cycle. COVID has shown that what the world needs is simple, fast and accurate diagnostic tests in large numbers. This is what we do. Sedia is dynamic, growing rapidly and is very relevant to the current global health crisis."
According to Nancy Lime, Vice President Operations, "Globally, an estimated 19% of persons living with HIV are unaware of their status. Individuals with recent HIV infections can be responsible for up to 40% of new infections in their community. Since HIV can remain asymptomatic and undetected for months, recently infected individuals can continue to pass the virus to others. New approaches and tools are needed to fight HIV and other global pandemics and this technology can potentially be applied to other diseases, including the SARS-CoV-2 'COVID-19' virus and sexually transmitted diseases."
More on Aussie Journal
- Consumer Accountability Alliance Issues Formal Notice Alleging Proximate Liability for Medical Harm
- A consortium of investors purchases the specialised plastic fabrication business, Viking Plastics
- Utah Metal Fabricator Titan Forge Builds Momentum with Custom Steel Projects and Spiral Staircases
- Jason Koch: Pioneering the Future of Real Estate Development in New Jersey
- Bach and Beyond: Cellists Return to the Beach for 2nd Annual Bethany Beach Cellofest
About Sedia Biosciences Corporation
Sedia Biosciences is a privately held medical device and diagnostics company founded in 2009 and is based in Beaverton, Oregon, USA. Our commitment is to become a leader in three areas intended to advance global access to care: (1) state-of-the-art rapid point-of-care diagnostic assays, (2) novel epidemiological disease surveillance assays and other Public Health tools and (3) innovative clinical specimen collection devices to improve and facilitate remote collection of specimens for follow-up testing. Sedia brings together a dedicated team of scientists and business people that share a common mission: to improve access to medical care around the world by providing innovative diagnostic, epidemiological and clinical products.
Follow us on Facebook, LinkedIn, Twitter or at our website: www.sediabio.com
Source: Sedia Biosciences Corporation
Filed Under: Health
0 Comments
Latest on Aussie Journal
- The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
- KidsBliss Nominated in Four Categories at 2025 Kiindred Awards
- Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
- The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
- Digital Watchdog Launches New myDW Cloud Services
- Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
- Drone Light Shows Emerge as the New Standard in Live Event Entertainment
- Lore Link is Here to Help Organize Your Game
- Chappaqua's Annual Townwide Summer Sale – Unbeatable Savings at Your Favorite Local Boutiques!
- Skyline Partners with ZenSpace to Offer Private Meeting Pods for Trade Show Exhibitors
- AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
- Construcción del Corredor Norte–Sur (NSC) de Singapur
- New Report: Slip and Fall Accidents Rank as the Leading Cause of Construction Site Fatalities
- Get Your Cowboy Boots On! Causeway Country BBQ Music Festival Kicks Off September 12–14 in Ft. Pierce
- Retired Hobbyist Launches Bold Weekly Album Project Using AI Songwriting Tools
- DimHum Launches Revolutionary CrowdShipping Service
- Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
- Infinite Health Introduces Cutting-Edge Regenerative Medicine for Wound Care with Trip Goolsby, MD
- Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews